Lexeo Therapeutics (LXEO) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $2.76, +4.94% vs the prior close of $2.63.
- Volume 1.30M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
LXEO jumps 4.9% to $2.76. Closed at $2.76, +4.94% vs the prior close of $2.63. Day range $2.61–$2.83, opened at $2.66.
LXEO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — LXEO jumps 4.9% to $2.76
- Closed at $2.76, +4.94% vs the prior close of $2.63. Day range $2.61–$2.83, opened at $2.66.
- Volume was 1.30M shares, 1.0x its 50-day average of 1.31M.
- Price is -34.1% vs its 50-day average ($4.19) and -50.3% vs its 200-day average ($5.56).
- 52-week range $2.56–$10.99; today's close sits at 2% of that range, 74.9% below the 52-week high.
Oct 14, 2026 — LXEO slides 4.0% to $2.63, a 52-week low, 3 down days in a row
- Closed at $2.63, -4.01% vs the prior close of $2.74. Day range $2.56–$2.79, opened at $2.70.
- Volume was 1.94M shares, 1.5x its 50-day average of 1.29M.
- Price is -37.7% vs its 50-day average ($4.22) and -53.0% vs its 200-day average ($5.60).
- 52-week range $2.56–$10.99; today's close sits at 1% of that range, 76.1% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — LXEO slides 9.9% to $2.74, a 52-week low
- Closed at $2.74, -9.87% vs the prior close of $3.04. Day range $2.74–$3.09, opened at $3.09.
- Volume was 1.59M shares, 1.2x its 50-day average of 1.27M.
- Price is -35.6% vs its 50-day average ($4.26) and -51.4% vs its 200-day average ($5.63).
- 52-week range $2.74–$10.99; today's close sits at 0% of that range, 75.1% below the 52-week high.
Oct 12, 2026 — LXEO slides 5.9% to $3.04, a 52-week low
- Closed at $3.04, -5.88% vs the prior close of $3.23. Day range $3.04–$3.22, opened at $3.22.
- Volume was 1.05M shares, 0.8x its 50-day average of 1.27M.
- Price is -29.1% vs its 50-day average ($4.29) and -46.4% vs its 200-day average ($5.67).
- 52-week range $2.98–$10.99; today's close sits at 1% of that range, 72.3% below the 52-week high.
Oct 9, 2026 — LXEO rises 0.6% to $3.23
- Closed at $3.23, +0.62% vs the prior close of $3.21. Day range $3.12–$3.34, opened at $3.21.
- Volume was 961.40K shares, 0.8x its 50-day average of 1.26M.
- Price is -25.0% vs its 50-day average ($4.31) and -43.4% vs its 200-day average ($5.71).
- 52-week range $2.98–$10.99; today's close sits at 3% of that range, 70.6% below the 52-week high.
Oct 8, 2026 — LXEO slides 3.0% to $3.21 on 2.1x normal volume
- Closed at $3.21, -3.02% vs the prior close of $3.31. Day range $3.11–$3.28, opened at $3.27.
- Volume was 2.55M shares, 2.1x its 50-day average of 1.23M — unusually heavy trading.
- Price is -25.9% vs its 50-day average ($4.33) and -44.1% vs its 200-day average ($5.75).
- 52-week range $2.98–$10.99; today's close sits at 3% of that range, 70.8% below the 52-week high.
Oct 7, 2026 — LXEO rises 0.3% to $3.31
- Closed at $3.31, +0.30% vs the prior close of $3.30. Day range $3.22–$3.46, opened at $3.27.
- Volume was 1.20M shares, 1.0x its 50-day average of 1.21M.
- Price is -23.9% vs its 50-day average ($4.35) and -42.8% vs its 200-day average ($5.78).
- 52-week range $2.98–$10.99; today's close sits at 4% of that range, 69.9% below the 52-week high.
Oct 6, 2026 — LXEO slides 3.2% to $3.30, 3 down days in a row
- Closed at $3.30, -3.23% vs the prior close of $3.41. Day range $3.17–$3.43, opened at $3.43.
- Volume was 1.54M shares, 1.3x its 50-day average of 1.20M.
- Price is -24.5% vs its 50-day average ($4.37) and -43.3% vs its 200-day average ($5.82).
- 52-week range $2.98–$10.99; today's close sits at 4% of that range, 70.0% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — LXEO slides 3.4% to $3.41
- Closed at $3.41, -3.40% vs the prior close of $3.53. Day range $3.37–$3.65, opened at $3.56.
- Volume was 1.86M shares, 1.6x its 50-day average of 1.18M.
- Price is -22.4% vs its 50-day average ($4.40) and -41.7% vs its 200-day average ($5.85).
- 52-week range $2.98–$10.99; today's close sits at 5% of that range, 69.0% below the 52-week high.
Oct 2, 2026 — LXEO dips 2.5% to $3.53 on 2.3x normal volume
- Closed at $3.53, -2.49% vs the prior close of $3.62. Day range $3.49–$3.69, opened at $3.66.
- Volume was 2.59M shares, 2.3x its 50-day average of 1.14M — unusually heavy trading.
- Price is -20.2% vs its 50-day average ($4.42) and -39.9% vs its 200-day average ($5.88).
- 52-week range $2.98–$10.99; today's close sits at 7% of that range, 67.9% below the 52-week high.
LXEO latest news & SEC filings
Every SEC filing by or about LXEO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.01 — Completed an acquisition or sale of assets.
- Item 3.02 — Sold unregistered shares.
Sep 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bhalla Narinder Pal received an award of 2,714 shares at $3.58 (≈$9.71K) on Sep 14, 2026; now holds 84,908
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Otero Jose Manuel received an award of 2,110 shares at $2.64 (≈$5.58K) on Sep 14, 2026; now holds 138,288
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Townsend Richard Nolan received an award of 2,306 shares at $2.64 (≈$6.10K) on Sep 14, 2026; now holds 376,778
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Tamayo Louis Edward sold 4,117 shares at $4.91 (≈$20.21K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Townsend Richard Nolan sold 3,345 shares at $4.95 (≈$16.56K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$25.87M (prior year -$26.10M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.30 (prior year -$0.60) (loss narrowed vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade LXEO
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 30, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.16% (largest 13.5%). That is a volatile stock.
- Liquidity: about 2.07M shares (≈$5.72M) trade per day on average.
- 52-week position: $2.76 vs a range of $2.56–$10.99 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Richard Nolan Townsend sold 3,345 shares on Aug 18, 2026.
- Latest filings: 8-K Sep 29, 2026; 8-K Sep 22, 2026; 10-Q Aug 12, 2026.
- Share count: 82.05M shares outstanding (Aug 10, 2026), +51.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
LXEO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 2.66 | 2.83 | 2.61 | 2.76 | 1.30M |
| Oct 14, 2026 | 2.70 | 2.79 | 2.56 | 2.63 | 1.94M |
| Oct 13, 2026 | 3.09 | 3.09 | 2.74 | 2.74 | 1.59M |
| Oct 12, 2026 | 3.22 | 3.22 | 3.04 | 3.04 | 1.05M |
| Oct 9, 2026 | 3.21 | 3.34 | 3.12 | 3.23 | 961.40K |
| Oct 8, 2026 | 3.27 | 3.28 | 3.11 | 3.21 | 2.55M |
| Oct 7, 2026 | 3.27 | 3.46 | 3.22 | 3.31 | 1.20M |
| Oct 6, 2026 | 3.43 | 3.43 | 3.17 | 3.30 | 1.54M |
| Oct 5, 2026 | 3.56 | 3.65 | 3.37 | 3.41 | 1.86M |
| Oct 2, 2026 | 3.66 | 3.69 | 3.49 | 3.53 | 2.59M |
| Oct 1, 2026 | 3.38 | 3.68 | 3.30 | 3.62 | 2.89M |
| Sep 30, 2026 | 3.44 | 3.59 | 3.28 | 3.38 | 3.05M |
| Sep 29, 2026 | 3.14 | 3.59 | 2.98 | 3.42 | 6.56M |
| Sep 28, 2026 | 3.27 | 3.29 | 3.14 | 3.14 | 1.26M |
| Sep 25, 2026 | 3.40 | 3.45 | 3.27 | 3.31 | 1.01M |
| Sep 24, 2026 | 3.50 | 3.50 | 3.33 | 3.39 | 1.48M |
| Sep 23, 2026 | 4.07 | 4.09 | 3.45 | 3.52 | 2.42M |
| Sep 22, 2026 | 4.31 | 4.33 | 4.03 | 4.07 | 3.09M |
| Sep 21, 2026 | 4.24 | 4.34 | 4.04 | 4.08 | 854.80K |
| Sep 18, 2026 | 4.16 | 4.22 | 4.06 | 4.20 | 2.29M |
About Lexeo Therapeutics
Lexeo Therapeutics (LXEO) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in NEW YORK, NY. Fiscal year ends December 31. SEC CIK 1907108.
LXEO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Mette Kirstine Agger | Director | Jun 29, 2026 |
| Steven Altschuler | Director | Jun 29, 2026 |
| Paula H Cholmondeley | Director | Jun 29, 2026 |
| Brenda Cooperstone | Director | Jun 29, 2026 |
| Reinaldo M Diaz | Director | Jun 29, 2026 |
| Laura Sepp-Lorenzino | Director | Apr 30, 2026 |
| Tolga Tanguler | Director | Jun 29, 2026 |
| Richard Nolan Townsend | Chief Executive Officer | Sep 28, 2026 |
| Hauwermeiren Timothy Van | Director | Jun 29, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Eric Adler | Chief Medical Officer | Nov 20, 2025 |
| Narinder Pal Bhalla | Chief Medical Officer | Sep 28, 2026 |
| Jose Manuel Otero | Chief Operating Officer | Sep 28, 2026 |
| Jenny Robertson | Chief Legal Officer | Nov 20, 2025 |
| Tai Sandi See | Chief Development Officer | Nov 20, 2025 |
| Louis Edward Tamayo | Chief Financial Officer | Sep 28, 2026 |
| Richard Nolan Townsend | Chief Executive Officer | Sep 28, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Richard Nolan Townsend | Sale | 3,345 | $4.95 |
| Aug 18, 2026 | Jose Manuel Otero | Sale | 1,304 | $4.96 |
| Aug 18, 2026 | Louis Edward Tamayo | Sale | 4,117 | $4.91 |
| Jul 1, 2026 | Jose Manuel Otero | Sale | 4,666 | $4.48 |
| Jul 1, 2026 | Narinder Pal Bhalla | Sale | 22,306 | $4.42 |
| Jul 1, 2026 | Louis Edward Tamayo | Sale | 4,641 | $4.49 |
| Jul 1, 2026 | Richard Nolan Townsend | Sale | 25,947 | $4.48 |
| May 18, 2026 | Jose Manuel Otero | Sale | 1,302 | $5.07 |
| May 18, 2026 | Richard Nolan Townsend | Sale | 3,342 | $5.06 |
| Apr 6, 2026 | Richard Nolan Townsend | Sale | 55,000 | $5.69 |
| Feb 18, 2026 | Richard Nolan Townsend | Sale | 10,173 | $6.38 |
| Feb 18, 2026 | Jose Manuel Otero | Sale | 3,016 | $6.40 |
| Nov 18, 2025 | Jenny Robertson | Sale | 549 | $9.27 |
| Nov 18, 2025 | Richard Nolan Townsend | Sale | 1,127 | $9.27 |
| Nov 18, 2025 | Eric Adler | Sale | 615 | $9.27 |
LXEO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-99.96M | -1.86 | $-98.56M |
| Dec 31, 2024 | — | $-98.33M | -3.09 | $-81.15M |
| Dec 31, 2023 | — | $-66.39M | -12.40 | $-59.50M |
| Dec 31, 2022 | $654.00K | $-59.28M | -36.36 | $-54.56M |
Latest balance sheet: total assets $254.90M, total liabilities $19.84M, cash $92.83M (as of Jun 30, 2026).
LXEO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $4.87 |
| May 11, 2026 | 8-K Item 2.02 (results) | $6.12 |
| Mar 30, 2026 | 8-K Item 2.02 (results) | $5.27 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $8.20 |
| Oct 17, 2025 | 8-K Item 2.02 (results) | $9.58 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $4.79 |
| May 12, 2025 | 8-K Item 2.02 (results) | $2.63 |
| Mar 24, 2025 | 8-K Item 2.02 (results) | $4.09 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $7.64 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 11, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on LXEO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.